LILRB4 is a regulator of NAFLD, and LILRB4 recruits SHP-1 to inhibit TNF receptor-associated factor 6 (TRAF6) ubiquitination, which in turn inhibits cascade inactivation of NF-κB and mitogen-activated protein kinase. Here, LILRB4 is linked to metabolic dysfunction-associated steatotic liver disease.